A long-awaited bounce for Old World shares relative to the U.S. hasn’t happened yet. But consider these cash-flow favorites from Oakmark International.
AstraZeneca has struck a licensing deal worth up to $2 billion for a weight-loss drug. Stockholders are welcoming the move as its shares have lagged peers.